The study will assess the safe and effective use of this drug for improving child health outcomes in a cohort in Uganda, led by the Infectious Diseases Institute and in South Africa, led by the University of Cape Town. The Liverpool International Child Neurodevelopment and Disabilities Group will support neurodevelopmental follow-up in Uganda.